Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.

A series of N-mustard derivatives of 9-anilinoacridine was synthesized for antitumor and structure-activity relationship studies. The alkylating N-mustard residue was linked to the C-3' or C-4' position of the anilino ring with an O-ethylene (O-C(2)), O-butylene (O-C(4)), and methylene (C(1)) spacer. All of the new N-mustard derivatives exhibited significant cytotoxicity in inhibiting human lymphoblastic leukemic cells (CCRF-CEM) in culture. Of these agents, (3-(acridin-9-ylamino)-5-{2-[bis (2-chloroethyl)amino]ethoxy}phenyl)methanol (10) was subjected to antitumor studies, resulting in an approximately 100-fold more potent effect than its parent analogue 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA) in inhibiting the growth of human lymphoblastic leukemic cells (CCRF-CEM) in vitro. This agent did not exhibit cross-resistance against vinblastine-resistant (CCRF-CEM/VBL) or Taxol-resistant (CCRF-CEM/Taxol) cells. Remarkably, the therapeutic effect of 10 at a dose as low as one tenth of the Taxol therapeutic dose [i.e., 1-2mg/kg (Q3Dx7) or 3mg/kg (Q4Dx5); intravenous injection] on nude mice bearing human breast carcinoma MX-1 xenografts resulted in complete tumor remission in two out of three mice. Furthermore, 10 yielded xenograft tumor suppression of 81-96% using human T-cell acute lymphoblastic leukemia CCRF-CEM, colon carcinoma HCT-116, and ovarian adenocarcinoma SK-OV-3 tumor models.

[1]  P. Cozzi,et al.  Phenyl sulfur mustard derivatives of distamycin A. , 2000, Bioorganic & medicinal chemistry letters.

[2]  T R Kelly,et al.  Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. , 1989, Journal of medicinal chemistry.

[3]  T. Chou,et al.  9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[4]  H. J. Creech,et al.  Heterocyclic derivatives of 2-chloroethyl sulfide with antitumor activity. , 1966, Journal of medicinal chemistry.

[5]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[6]  R. D'Alessio,et al.  Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. , 1989, Journal of medicinal chemistry.

[7]  R. C. Brown,et al.  An expedient synthesis of 3-amino-5-hydroxy- benzoic acid and its n-alkyl analogues , 1983 .

[8]  Ting-Chao Chou,et al.  Synthesis of cyclopentanthraquinones: analogs of mitomycin C , 1993 .

[9]  T. Chou,et al.  Synergism and antagonism in chemotherapy , 1991 .

[10]  Peter J Houghton,et al.  Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. , 2003, Cancer research.

[11]  W. Denny,et al.  DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. , 1990, Journal of medicinal chemistry.

[12]  H. J. Creech,et al.  Antitumor and mutagenic properties of a variety of heterocyclic nitrogen and sulfur mustards. , 1972, Journal of medicinal chemistry.

[13]  W. Denny,et al.  DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards. , 1991, Journal of medicinal chemistry.

[14]  R. Souhami,et al.  Structure-activity relationship of a series of nitrogen mustard- and pyrrole-containing minor groove-binding agents related to distamycin. , 1994, Anti-cancer drug design.

[15]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[16]  Alberto Martínez,et al.  Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A. , 2002, Journal of medicinal chemistry.

[17]  T. Chou,et al.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Liu,et al.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. , 1986, Cancer research.

[19]  M. Brendel,et al.  Relationships between functionality and genetic toxicology of selected DNA-damaging agents. , 1984, Mutation research.

[20]  W. Denny,et al.  DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. , 1990, Journal of medicinal chemistry.

[21]  T C Chou,et al.  Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline. , 1999, Journal of medicinal chemistry.

[22]  D. Vistica,et al.  Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. , 1983, Biochemical pharmacology.

[23]  B. Nilsson,et al.  Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. , 1987, Cancer research.

[24]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[25]  G. Weiss,et al.  A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Pérahia,et al.  The molecular electrostatic potential of the B-DNA helix , 1979 .

[27]  J. Hartley,et al.  Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: synthesis and antitumour activity. , 2002, Bioorganic & medicinal chemistry.

[28]  G. Spalluto,et al.  PNU 157977: a new potent antitumour agent exhibiting low in vivo toxicity in mice injected with L1210 leukaemia cells. , 1999, Anti-cancer drug design.

[29]  W. Denny,et al.  DNA-directed alkylating ligands as potential antitumor agents: sequence specificity of alkylation by intercalating aniline mustards. , 1990, Biochemistry.

[30]  J. Hartley,et al.  Alkylation specificity for a series of distamycin analogues that tether chlorambucil. , 1997, Anti-cancer drug design.

[31]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[32]  A. Dayan.  Carcinogenicity of Alkylating Cytostatic Drugs , 1987 .

[33]  L. Liu,et al.  Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Singer.  The chemical effects of nucleic acid alkylation and their relation to mutagenesis and carcinogenesis. , 1975, Progress in nucleic acid research and molecular biology.

[35]  T. Chou,et al.  Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. , 2004, Bioorganic & medicinal chemistry letters.

[36]  H. Tabuchi,et al.  GTP induces knotting, catenation, and relaxation of DNA by stoichiometric amounts of DNA topoisomerase II from Bombyx mori and HeLa cells. , 1988, The Journal of biological chemistry.

[37]  W. Denny,et al.  Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity. , 1997, Anti-cancer drug design.